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Preserving Survival Time (RPSFT) model were used as secondary analyses. The
Inverse Probability of Censoring Weights (IPCW) method and the Cox model using
treatment as a time-dependent covariate were used as sensitivity analyses.
RESULTS: Overall, 71% of patients randomized to dexamethasone crossed over to
bortezomib. The primary analysis led to a hazard ratio of 0.59 (95%CI: [0.32,0.86]) for
bortezomib versus dexamethasone, compared to 0.77 (95%CI: [0.61,0.97]) using the
ITT approach. The results of the secondary analyses were consistent with the
primary analysis. The IPCW provided results, which were very sensitive to the
choice of the time interval. Lastly, the Cox model with treatment as a time-depen-
dent variable resulted in a counter-intuitive higher hazard ratio than the ITT anal-
ysis, consistent with results from simulation studies indicating this approach is
biased.CONCLUSIONS:Adjusting for crossover led to a decrease of the hazard ratio
from 0.77 to 0.59, and resulted in wider confidence intervals than the ITT analysis.
Additional analyses are required to assess the performance of the IPCW method
compared to the IPE algorithm and the RPSFT model under different scenarios.
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OBJECTIVES: Develop budget impact model to forecast total cost of treatment for
cutaneous T-cell lymphoma (CTCL) for US public and private payer.METHODS:The
clinical efficacy and safety data were obtained from the published pivotal study
results. Costs of adverse events were estimated based on claims database analysis,
AHRQ’s HCUP and CMS Medicare 2009 databases. Drug cost was estimated based
on 2011 AWP price. Epidemiology data were obtained from NCI-SEER and CDC
databases. A budget impact model was implemented over a period of five years,
based on a stable population and on different penetration and substitution rates of
newly approved therapy. Model was developed in excel based format. Blinded
Model design and outputs were tested with payers and KOLs. RESULTS: For rare
cancers such as CTCL, the budget impact of treatment with targeted cancer therapies
is in the range of $460,000-$530,000 per 1 million covered lives. The per patient per
member (PPPM) budget impact of this treatment is 46-53 cents. Medical cost offsets
were estimated but were insignificant compared to total cost of treatment. US payers
rated PPPM output as the one of the most important relevant outputs of model.
CONCLUSIONS: This budget impact model shows that new treatments for rare
forms of cancer are likely to have minimal budget impact on payers. PPPM based
outputs are more relevant to payers, than per patient treatment costs. However, an
emerging concern is the total budget impact of all therapies indicated for ultra-
orphan disorders, which might be an important consideration for future models.
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OBJECTIVES:Digital mammography is costlier than screen film mammography but
presents benefits at the technological and logistic level. The aim of this study was
to analyze the budget impact and the health benefits of the introduction of digital
mammography in a population-based breast cancer screening program.
METHODS: A discrete-event simulation model was implemented including the
processes under a breast cancer screening program and the natural history of
breast cancer. The screening events included: invitation (biennial) of the target
population (women aged 50-69 years), participation, screening test, confirmatory
tests after a positive mammography result, cancer diagnosis and treatment. Nat-
ural history of breast cancer included the following health states: no cancer, pre-
clinical (non symptomatic) cancer, clinical (or symptomatic) cancer and death.
Digital and analogical mammography had the same sensitivity, but different spec-
ificities were applied according to type of mammography and also initial or suc-
cessive screening. Results were collected during a 20-year screening scenario.
RESULTS: A total of 90,575 women were screened under both techniques during
the simulated 20 years. This population resulted in more than 262,500 screening
mammograms. The recall rate was 5.9% under digital mammography and 6.4%
under analogical mammography, while the numbers of confirmatory tests needed
were 23,728 and 32,697, respectively. The cancer detection rate was 0.7% for both
techniques. Digital mammography saved 1.909.167 euros in additional tests, while
it was 1.026.807 euros more expensive in screening mammograms and presented
similar costs of treatments. CONCLUSIONS: Results suggest that, although popu-
lation-based breast cancer screening with digital mammography is costlier in
terms of screening mammographies, it saves money in terms of additional tests
needed. The health benefits are similar to those of conventional analogical mam-
mography, but it reduces the number of additional tests needed, which represent a
clear benefit to participating women.
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OBJECTIVES: The addition of MEPACT as an add-on treatment to adjuvant chemo-
therapy in the treatment of high-grade non-metastatic osteosarcoma after macro-
scopically complete surgical resection has been shown to significantly increase
overall survival of young patients. This study assessed the costs (drug and admin-
istration) and the long-term financial impact on the UK (UK) government of intro-
ducing MEPACT. METHODS: Based on the cost of MEPACT and using survival rates
derived from a clinical trial, we projected the net budgetary impact of MEPACT
compared to no MEPACT. Further, we modelled the net tax contribution to the state
of a surviving patient over a lifetime by subtracting direct government transfers
that are made to the individual (child benefit, education etc) from the individual’s
gross tax contribution based on average anticipated earnings. RESULTS: Using UK
incidence rates of osteosarcoma the model estimated approximately 54 newly di-
agnosed non-metastatic cases per year. Assuming that 38 doses of MEPACT (cal-
culated from trial data) are added to the treatment regimen of 50% of patients at a
cost of £91,189 , the expected 1-year cost would be UK £3,972k compared with
£1,450k had all patients been treated without MEPACT. Administration costs ac-
counted for 3% of total costs. The lifetime discounted value of net taxes from a 14
year old patient treated with MEPACT is £79,000. The breakeven age, defined as the
point at which the net tax contribution becomes greater than zero, is approxi-
mately 41 years. CONCLUSIONS: The additional budget impact due to MEPACT is
mainly due to the cost of the drug. From the tax calculations, we conclude that
investment in MEPACT does not negatively impact the long run fiscal budget of the
UK government. Conversely, by taking a broader government perspective over an
average lifetime, a surviving patient returns a positive net value to the State.
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OBJECTIVES: To evaluate the budget impact of nilotinib for newly diagnosed pa-
tients with chronic myeloid leukemia (CML) for the health care system in Bulgaria.
METHODS: Current standard of therapy (imatinib) is compared with the newly
authorized for sale nilotinib and dasatinib used as a first line therapy. Cost of yearly
pharmacotherapy and adverse drug reactions management have been calculated
for 3 years for different proportions of newly diagnosed patients with CML in
chronic phase. The exchange rate is 1 BGN  0.51 EUR. RESULTS: Clinical studies
shows significant benefits from nilotinib but the question remains if it is worth the
cost of therapy. Calculation of the yearly pharmacotherapy cost per 100 patients
arranges the medicines in monetary value order as follows: 5,398,092 BGN for ima-
tinib, 6,564,681 BGN for nilotinib, and 8,365,872 BGN for dasatinib. Weighed cost by
the probability of appearing of the ADR is 733.26 BGN for imatinib, 509.75 for nilo-
tininb, and 1,010.29 BGN for dasatinib. The relative share of patients treated with
nilotinib in first line is 12% for the first year, 32% for the second, and 38% for the
third year. The introduction of nilotinib will change the budget for all patients with
CML to 6,895,316 in comparison with 6,725,246 BGN before the introduction, to
7,177,671 BGN in the second year, and to 7,262,378 BGN in the third year. Thus the
over all increase for the observed 3 years will be within 179,044 BGN.
CONCLUSIONS: The introduction of nilotinib as first line therapy for patients with
newly diagnosed CML will lead to relatively small increase in the health care bud-
get in Bulgaria compared to the clinical benefit in terms of achievement of deeper
response, improvement of overall survival and less disease progression.
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OBJECTIVES: Capecitabine (C) is approved in Brazil for the treatment of breast
cancer (BC), 2nd or subsequent lines. In the private sector, it’s not often used, due
to the fact that health insurance plans (HI) do not offer coverage for oral (PO)
chemotherapy (CHEMO), only for intravenous (IV). Our aim was to determine if the
use of C could spare costs if adopted by HI. METHODS: We searched Evidencias
Database for BC patients eligible for the use of C, in the year of 2008. This database
has information from over 2 million of users of 14 HI. We identified the IV CHEMO
actually used and the costs paid. Then, based on the data of each individual patient
and in the length of use of CHEMO, we calculated the associated costs in a scenario
where C replaced the IV CHEMO used. Also, we performed some sensitivity analysis
based on different percentages of substitutions of IV by PO chemo. We considered
only the prices of drugs. RESULTS: We found 518 BC patients eligible for C use.
These patients received 3581 cycles of chemotherapy (Paclitaxel, Docetaxel, Gem-
citabine, Vinorelbine, Doxorubicin). The total cost for these treatments were US$ 5
364 000. If C replaced 100% of the IV CHEMO, the total cost would drop to
US$2,078,000, 62% smaller than the IV alternative. In a simulation, where 60% of the
patients would use the IV option and 40% would use C, the total cost would also be
smaller: US$4,050,000, 25% smaller than when IV route is used exclusively.
CONCLUSIONS: The adoption of C by HI in Brazil is cost-saving for BC patients.
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BUDGETARY IMPACT OF ADOPTION OF ERLOTINIB FOR LUNG CANCER IN THE
PRIVATE HEALTH INSURANCE MARKET IN BRAZIL: A REAL WORLD DATA
ANALYSIS
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